Combined with the clinical data, our findings indicate that increased PC expression and activity could be essential for survival of mutant IDH1 cells and, as such, could serve as a potential therapeutic target for mutant IDH1 gliomas either alone or in combination with other therapies. The gene discussed is IDH1; the disease is central nervous system cancer.